Last Update 03 Feb 26

Fair value Increased 13%

NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook

Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research.

Analyst Commentary

Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.

Bullish Takeaways

Bullish analysts see the higher price target as a sign that their base case for future earnings potential can support a richer P/E than before, even after applying a discount rate they consider appropriate for the current risk profile.
They view the latest work on fair value as better aligned with recent Street research, which they interpret as a step toward a more consistent view on where revenue growth and profit margins could settle over time.
Supportive commentary highlights that updated assumptions around long term revenue and margin structure give room for upside if NeuroPace can execute efficiently on its current commercial and operational plans.
Bullish analysts often point to the fact that a higher target, even by a relatively small absolute amount, can still matter when compounded over a multi year investment horizon, especially if execution stays on track with Street expectations.

Bearish Takeaways

More cautious analysts focus on the idea that the price target move is incremental, not transformational. In their view this limits the margin of safety if execution or market conditions fall short of current assumptions.
They point out that the fair value calculations still rely on specific views about future revenue growth, profit margins, and exit P/E, any of which could differ from actual outcomes and put pressure on valuation.
Some highlight that using a particular discount rate can materially affect the implied price target. They therefore question how sensitive the new target is to changes in perceived risk or funding costs.
Bearish analysts also emphasize that Street research can converge around similar models, which might reduce the diversity of views and leave less room for error if key inputs such as growth expectations or profitability timing do not play out as modeled.

What's in the News

Issued earnings guidance for the first quarter of fiscal 2026 with expected revenue of about US$21 million to US$22 million, and full year 2026 total revenue guidance of US$98 million to US$100 million for the business, including core RNS revenue assumptions (Corporate guidance).
Filed a Premarket Approval Supplement with the FDA to expand the RNS System label to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures. This filing is supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a safety profile described as favorable for this patient group (Product related announcement).
Presented preliminary 18 month NAUTILUS1 trial results at the American Epilepsy Society meeting. The results reported a 77% median reduction in GTC seizures from baseline, rapid and sustained reductions in generalized seizures over time, and Clinical Global Impression of Change above 80% for both physicians and patients. Safety results were described as consistent with the existing RNS profile (Product related announcement).
Outlined plans for the 2025 American Epilepsy Society Annual Meeting. The RNS System and NeuroPace AI platform are set to feature in sessions on long term seizure reduction data, idiopathic generalized epilepsy outcomes, and clinical best practices for responsive neuromodulation programs (Product related announcement).

Valuation Changes

Fair Value: Price target fair value moved from about US$17.13 to roughly US$19.43 per share, suggesting a modestly higher central estimate.
Discount Rate: The discount rate shifted slightly from about 8.03% to roughly 7.96%, indicating only a small change in the risk or funding assumptions used in the model.
Revenue Growth: The revenue growth assumption moved from about 18.62% to roughly 11.46%, pointing to a more conservative view on top line expansion in the forecast period.
Net Profit Margin: The net profit margin assumption edged from roughly 12.34% to about 12.92%, reflecting a slightly higher expected profitability level in the model.
Future P/E: The future P/E input moved marginally from about 49.71x to roughly 50.42x, indicating a small change in the multiple applied to projected earnings.

6 views

Key Takeaways

Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.
AI-enhancements and clinical program advancements promise operational efficiency, new revenue streams, and improved financial performance.
NeuroPace's growth strategy relies on ambitious expansions, new product success, and increased prescriber engagement, yet faces risks from resource strain and market adoption challenges.

Catalysts

About NeuroPace

Operates as a medical device company in the United States.What are the underlying business or industry changes driving this perspective?

Expanding adoption and utilization within Level 4 comprehensive epilepsy centers could significantly increase revenue by tapping into a $2 billion annual core market opportunity.
Project CARE aims to expand site of service delivery and has begun contributing to revenue growth; doubling implants and referrals can further drive revenue increases.
Advancing key clinical development programs to expand indications of use for the RNS System suggests potential new revenue streams and market expansion, positively impacting future earnings.
Introduction of AI-enabled software tools and next-generation platform improvements might enhance operational efficiency and patient outcomes, potentially boosting both revenue and net margins.
Strengthened balance sheet post-public offering supports strategic growth initiatives and operating expansions, aiming for cash flow breakeven and improved earnings.

NeuroPace Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming NeuroPace's revenue will grow by 18.6% annually over the next 3 years.
Analysts are not forecasting that NeuroPace will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate NeuroPace's profit margin will increase from -29.4% to the average US Medical Equipment industry of 12.3% in 3 years.
If NeuroPace's profit margin were to converge on the industry average, you could expect earnings to reach $17.4 million (and earnings per share of $0.43) by about August 2028, up from $-24.8 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 49.7x on those 2028 earnings, up from -11.8x today. This future PE is greater than the current PE for the US Medical Equipment industry at 29.3x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.03%, as per the Simply Wall St company report.

NeuroPace Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

NeuroPace's rapid expansion strategy at Level 4 comprehensive epilepsy centers and outside of them with Project CARE depends on significant increases in implants and referrals, which might strain their resources and potentially affect revenue if expected growth doesn't materialize as projected.
The company's 2025 revenue guidance is heavily reliant on the success of new product offerings and indications, such as the NAUTILUS pivotal study and pediatric RNS indications. Regulatory or clinical trial setbacks could delay these expansions and impact forecasted revenue growth.
While gross margins are currently healthy, potential fluctuations in the mix of distributed product lines, like DIXI Medical, which carry lower margins, could pressure overall gross margins, impacting profitability.
The company's reliance on increasing prescriber numbers and direct-to-consumer marketing for revenue growth might incur higher-than-anticipated expenses, affecting their net income and ability to achieve cash flow breakeven.
NeuroPace's significant investments in AI-enabled software tools and new technologies aim for long-term gains, but if deployment or adoption is slower than expected, it could impact short-to-medium-term earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $17.125 for NeuroPace based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $15.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $140.7 million, earnings will come to $17.4 million, and it would be trading on a PE ratio of 49.7x, assuming you use a discount rate of 8.0%.
Given the current share price of $8.92, the analyst price target of $17.12 is 47.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on NeuroPace?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Expanding Level 4 Epilepsy Centers Will Unlock Future Potential